MedTrace Logo

Safety and Efficacy of Drug Combinations Against Schistosomiasis

NCT01050374 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 650

Last updated 2010-01-15

No results posted yet for this study

Summary

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of MBD in combination with PZQ in the treatment of SCH and STH in children aged 1-15 years of age.

Conditions

  • Parasitic Diseases

Interventions

DRUG

albendazole + praziquantel

albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)

DRUG

mebendazole + praziquantel

mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)

Sponsors & Collaborators

  • DBL -Institute for Health Research and Development

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01050374 on ClinicalTrials.gov